cAMP Dependent PK Inhibitor, PKI (14-24), amide

cAMP Dependent PK Inhibitor, PKI (14-24), amide (CPC catalog code PKCP-006) is a synthetic kinase / phosphatase substrate in the kinase substrates category. It is provided as a lyophilized ~1 mg vial for in-vitro research use only.

Published and internal research programs use cAMP Dependent PK Inhibitor, PKI (14-24), amide as a reference standard in kinase substrates workflows — for example, kinase activity and kinetic characterization and high-throughput inhibitor screening. Human clinical evidence is not established.

No. cAMP Dependent PK Inhibitor, PKI (14-24), amide is a research-grade reference peptide and is not approved by the FDA or any national regulator for human or veterinary therapeutic use. It is offered exclusively for in-vitro laboratory research and does not ship to the United States for consumer use.

In a kinase substrates workflow, cAMP Dependent PK Inhibitor, PKI (14-24), amide is reconstituted in sterile buffer or DMSO (solubility-dependent) and applied in the researcher's chosen assay format. ADP-Glo, HTRF KinEASE, and radiometric filter-binding assays.

Store lyophilized at −20 °C, protected from light and moisture. Follow your institution's standard operating procedures for handling synthetic peptides.

This kindr reference page mirrors CPC Scientific's catalog metadata for PKCP-006. The upstream reference sheet — including sequence, purity, MW, and application notes where published — is linked from the buy panel. All orders placed on kindr Peptides ship internationally under research-use terms only.

Research-grade peptides in the CPC catalog are synthesized by solid-phase peptide synthesis (SPPS), purified by preparative RP-HPLC, and characterized by analytical HPLC and mass spectrometry. Typical purity is ≥95%; certificate of analysis is available on request.